Global Information
회사소개 | 문의 | 위시리스트

RNAi : 기술과 세계 시장

RNAi Technologies and Global Markets

리서치사 BCC Research
발행일 2016년 01월 상품 코드 166047
페이지 정보 영문 176 Pages
가격
US $ 2,750 ₩ 3,255,000 PDF by E-mail (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄기능에 제약은 없으나 원칙적으로 허용된 인쇄횟수는 1회이며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 3,300 ₩ 3,906,000 PDF by E-mail (2-5 Users) help
동일 사업장 내 5명까지 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄기능에 제약은 없으나 원칙적으로 허용된 인쇄횟수는 5회까지이며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 3,960 ₩ 4,687,000 PDF by E-mail (Site License) help
동일 사업장 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,752 ₩ 5,625,000 PDF by E-mail (Enterprise License) help
동일 기업 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


RNAi : 기술과 세계 시장 RNAi Technologies and Global Markets
발행일 : 2016년 01월 페이지 정보 : 영문 176 Pages

세계의 RNA 간섭 기술 시장은 2015년의 26,210만 달러에서 2020년까지 CAGR 8.4%로 확대되며, 39,260만 달러에 달할 것으로 예측됩니다.

세계 RNAi 기술 시장의 개요와 동향, 2020년까지의 성장 예측, 기술 동향, RNAi 연구 툴, 시약, 약제 개발, 진단, 농업의 상업적 기회 및 진출 기업 개요 등을 정리하여 전해드립니다.

제1장 서론

제2장 개요

제3장 개관

  • 리보핵산
  • RNA 간섭(RNAi)
  • RNA 간섭 약물전달
  • RNAi Drug Discovery와 개발
  • 기타 잠재적 응용

제4장 신규 개발과 법규제 활동

  • 신규 개발
  • 법규제 측면
  • 제휴적 임상시험과 향후 활동

제5장 시장 분석

  • 기술별 시장
  • 시장 점유율
  • RNA 간섭 연구 툴과 시약
  • 치료제
  • 세계의 의약품 시장
  • RNAi 진단약
  • 농업에서의 RNA 간섭
  • 지역별 시장

제6장 업계 구조

  • 연구 툴과 시약
    • 시장 리더
    • 시장 점유율
  • 진단약
    • 시장 리더
    • 시장 점유율

제7장 특허 분석

제8장 현황

제9장 기업 개요

제10장 부록

도표

KSA 16.01.28

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

REPORT HIGHLIGHTS

The global market for RNA Interference technologies is expected to grow from $262.1 million in 2015 to $392.6 million in 2020, registering a compound annual growth rate (CAGR) of 8.4%.

This report provides:

  • An overview of the global market for RNAi technologies which are used in the areas of drug delivery, therapeutics, and diagnostics
  • Analyses of global market trends, with data from 2014, estimates for 2015, and projections of compound annual growth rates (CAGRs) through 2020
  • A breakdown of the technologies: RNAi for drug delivery (by nanoparticle delivery, nucleic acid delivery, aptamer delivery); RNAi for drug discovery and therapeutics (by diseases); RNAi for disease diagnostics and biomarker development (by diseases); and RNAi for reagents, research tools, and other applications (by application)
  • Examination of significant deals in the RNAi technologies sector during the last decade
  • A look at commercial opportunities in the RNAi research tools and reagents, drug development, diagnostic, and agriculture markets
  • Profiles of major players in the industry

SCOPE OF THE STUDY

BCC Research conducted the market assessment, the global and regional breakdown of sales data, market projection for the commercial RNAi technologies, application of the techniques in commercial sector as well as in research and development. Further, BCC Research offers the details of new developments, patent analysis, market leaders and market share, etc. for the RNAi technologies and its applications.

The report summarizes the global RNAi technologies market by category and by region. The RNAi market is analyzed based on RNAi research tools and reagents as well as on RNAi diagnostics. The research tools and reagents and therapeutics considered in this report are mainly for small/short interfering RNAs (siRNAs) and diagnostics are mainly based on microRNAs (miRNAs).

MicroRNA (miRNA) research tools, services, drug discovery etc. are excluded from this report; however, these areas are worth a separate report and thus are analyzed in BCC Research report BIO115B in detail. U.S. and non-U.S. markets are considered for the geographical market analysis. The prospective application of RNAi therapeutics in various disease classifications such as oncological, cardiovascular, neurodegenerative, ophthalmologic and others are discussed. The application and progress of RNAi technologies in agriculture is also discussed in this report.

BCC Research verified the sales data for the global and regional RNAi markets for the present and projected values through statistical analysis. The tools/technology details in the report are based on their present and their prospective application and suitability.

ANALYST CREDENTIALS

The study has been carried out by a team of professionals in the biotechnology industry. The project manager is Shalini S. Dewan, who holds a master's degree in pharmaceutical chemistry and has over 14 years of industry experience. She was awarded a Gold Medal by the Prime Minister of India for her work and has worked with top companies in India and in the U.S.

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY OBJECTIVES
  • REASONS FOR DOING THIS STUDY
  • CONTRIBUTIONS OF THE STUDY AND INTENDED AUDIENCE
  • SCOPE OF THE STUDY
  • METHODOLOGY
  • INFORMATION SOURCES
  • ANALYST CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 - EXECUTIVE SUMMARY

  • SUMMARY TABLE GLOBAL REVENUE FOR RNA INTERFERENCE TECHNOLOGIES BY TYPE, THROUGH 2020 ($ MILLIONS)
  • SUMMARY FIGURE GLOBAL REVENUE FOR RNA INTERFERENCE TECHNOLOGIES BY TYPE, 2013-2020 ($ MILLIONS)

CHAPTER 3 - OVERVIEW

  • RIBONUCLEIC ACID (RNA)
    • EVOLUTION OF RNA
      • TABLE 1: EVOLUTION OF RNA
  • RNA INTERFERENCE (RNAI)
    • MECHANISM OF ACTION OF RNA INTERFERENCE
      • MicroRNA (miRNA)
        • TABLE 2: MICRORNA (MIRNA) DATABASES
      • Short Interfering RNA (siRNA)
        • TABLE 3: SHORT/SMALL INTERFERING RNA (SIRNA) DATABASES
      • Small Hairpin RNA (shRNA)
      • Piwi-Interacting RNA (piRNA)
        • TABLE 4: PIWI-INTERACTING RNA (PIRNA) DATABASES
  • RNA INTERFERENCE DRUG DELIVERY
    • SYSTEMIC ELIMINATION OF SIRNA
    • SIRNA STABILITY IN BLOODSTREAM
    • RETICULOENDOTHELIAL SYSTEM (RES) ENTRAPMENT
    • VASCULAR ENDOTHELIUM
    • DIFFUSION
    • PLASMA MEMBRANE
    • ENDOSOMAL ENTRAPMENT
    • NANO-CARRIER MEDIATED TOXICITY
    • METHODS OF RNA INTERFERENCE DRUG DELIVERY SYSTEMS
      • Physical RNAi Delivery Methods
        • Hydrodynamic Injection
        • Electroporation
      • Vector-Based RNAi Delivery Methods
        • Plasmid Vector RNAi Delivery
        • Virus Vector RNAi Delivery
      • Carrier-Based Nonviral RNAi Delivery
        • Cationic Cell-Penetrating Peptide (CPP)
        • Aptamer
        • Lipid-Based siRNA Delivery
          • TABLE 5: STABILIZATION METHODS FOR LIPID BASED SIRNA DELIVERY SYSTEM
      • Polymer- and Peptide-Based Vector
      • Lipid-Polymer Combination
      • Dendrimers
      • Phi29 Packaging RNA
      • Mesoporous Silica Nanoparticles
      • Antibodies
      • Stem Cell
      • Light-Controlled Delivery
      • Quaternized Starch Based Carrier
  • RNAI DRUG DISCOVERY AND DEVELOPMENT
    • RNA-BASED THERAPIES
      • Antisense RNA Therapy
      • Ribosome RNA Therapy
      • Aptamer RNA Therapy
      • Messenger RNA (mRNA) Therapeutics
      • RNAi Therapeutics
        • Drug Discovery
          • Targeting miRNA Processes
          • Delivering Designed siRNAs Into Cells
        • Drug Target Validation
        • Designing RNAi Therapeutics
          • Sequence Selection
          • Chemical and Structure Modification
        • Drug Development
          • RNAi Instability
          • Off-Target Effects
          • Innate/Intrinsic Immune Response
          • Delivery Material Toxicity
          • Saturation of RNAi Machinery
  • OTHER POTENTIAL APPLICATIONS OF RNA INTERFERENCE
    • DIAGNOSTICS
    • AGRICULTURE

CHAPTER 4 - NEW DEVELOPMENTS AND REGULATORY ACTIVITY

  • NEW DEVELOPMENTS
    • TABLE 6: NEW DEVELOPMENTS IN THE RESEARCH PIPELINE OF RNAI THERAPEUTICS AND TECHNOLOGIES AS OF SEPTEMBER 2015
  • REGULATORY ASPECTS
    • REGULATORY DEVELOPMENTS
  • COLLABORATIVE TRIALS AND FUTURE ACTIVITIES

CHAPTER 5 - MARKET ANALYSIS

  • MARKET BY TECHNOLOGY
    • TABLE 7: GLOBAL REVENUE FOR RNAI TECHNOLOGIES BY TYPE, THROUGH 2020 ($ MILLIONS)
    • FIGURE 1: GLOBAL REVENUE FOR RNAI TECHNOLOGIES BY TYPE, 2013-2020 ($ MILLIONS)
  • MARKET SHARE
    • TABLE 8: MARKET SHARE OF RNAI TECHNOLOGIES BY TYPE, 2014 (%)
    • FIGURE 2: MARKET SHARE OF RNAI TECHNOLOGIES BY TYPE, 2014 (%)
  • RNA INTERFERENCE RESEARCH TOOLS AND REAGENTS
    • RNAi Research Tools and Constructs
      • TABLE 9: MODIFICATIONS OF SIRNA
      • TABLE 10: RNAI VECTORS
      • Reagents
    • Market Overview
    • Market Revenue
      • TABLE 11: GLOBAL REVENUE FOR RNAI RESEARCH TOOLS AND REAGENTS, THROUGH 2020 ($ MILLIONS)
      • FIGURE 3: GLOBAL REVENUE FOR RNAI RESEARCH TOOLS AND REAGENTS, 2013-2020 ($ MILLIONS)
    • Market Share
      • TABLE 12: MARKET SHARE OF RNAI RESEARCH TOOLS AND REAGENTS, 2014 (%)
      • FIGURE 4: MARKET SHARE OF RNAI RESEARCH TOOLS AND REAGENTS, 2014 (%)
  • RNAI INTERFERENCE THERAPEUTICS
    • TABLE 13: DISEASE-SPECIFIC TARGET GENES/PROTEINS FOR RNAI THERAPEUTICS
  • GLOBAL PHARMACEUTICAL MARKET
    • TABLE 14: GLOBAL PHARMACEUTICAL MARKET, THROUGH 2020 ($ BILLIONS)
    • FIGURE 5: GLOBAL PHARMACEUTICAL SALES MARKET,2013-2020 ($ BILLIONS)
    • Market Share of Pharmaceutical Products by Region
      • TABLE 15: GLOBAL PHARMACEUTICAL MARKET SHARES BY REGION, 2014 (%)
      • FIGURE 6: GLOBAL PHARMACEUTICAL MARKET SHARES BY REGION, 2014 (%)
    • Sales of Top Pharmaceutical Companies
      • TABLE 16: TOP GLOBAL PHARMACEUTICAL COMPANIES BY SALES, 2014 ($ MILLIONS)
    • Diseases
      • Cardiovascular Disease
      • Pulmonary Disease
      • Central Nervous System (CNS) Disease
        • Alzheimer's Disease (AD)
        • Parkinson's Disease (PD)
        • Huntington's Disease (HD)
      • Oncology
        • Breast Cancer
        • Pancreatic Cancer
        • Ovarian Cancer
        • Liver Cancer
        • Renal Cancer
        • Colon Cancer
        • Lung Cancer
        • Brain Tumor
        • Prostate Cancer
      • Age-Related Macular Degeneration (AMD)
      • Global Outlook of Therapeutic Spending for Certain Diseases
        • TABLE 17: GLOBAL OUTLOOK OF THERAPEUTIC SPENDING BY DISEASE, THROUGH 2018 ($ BILLION/%)
      • Market Overview
  • RNAI DIAGNOSTICS
    • TABLE 18: NUMBER OF PUBLICATIONS ASSOCIATED WITH MIRNA AND DISEASES, OCTOBER 2015
    • miRNA in Cancer Diagnostics
      • TABLE 19: MIRNA IN VARIOUS CANCER TYPES
      • TABLE 20: MIRNA AND TARGET GENE PAIRS IN VARIOUS CANCER TYPES
    • miRNAs as Diagnostic, Prognostic and Predictive Biomarkers
      • TABLE 21: BIOMARKERS IN VARIOUS CANCER TYPES
    • Market Overview
    • Market Revenue
      • TABLE 22 GLOBAL REVENUE MARKET FOR RNAI DIAGNOSTICS, THROUGH 2020 ($ MILLIONS)
      • FIGURE 7 GLOBAL REVENUE MARKET FOR RNAI DIAGNOSTICS, 2013-2020 ($ MILLIONS)
    • Revenue for Global mRNA Research Tools Market
      • TABLE 23: GLOBAL REVENUE FOR MIRNA RESEARCH TOOLS, THROUGH 2020 ($ MILLIONS)
      • FIGURE 8: GLOBAL REVENUE FOR MIRNA RESEARCH TOOLS,2013-2020 ($ MILLIONS)
  • RNA INTERFERENCE IN AGRICULTURE
    • Virus Control Through RNAi
    • Safety Concerns
      • TABLE 24: SAFETY ISSUES WITH RNAI CROP IMPROVEMENT
    • RNAi In Crops
      • TABLE 25: PLANT IMPROVEMENT AREAS THROUGH RNAI TECHNOLOGIES
      • TABLE 26: REGIONS, GENES AND APPLICATION OF RNAI-TARGETING ORGANISMS FOR IMPROVEMENT OF CROPS
    • RNAi In Aquaculture
    • Market Overview
  • MARKET BY REGION
    • MARKET OVERVIEW
    • MARKET REVENUE
      • RNAi Research Tools and Reagents
        • TABLE 27: GLOBAL REVENUE FOR RNAI RESEARCH TOOLS AND REAGENTS BY REGION, THROUGH 2020 ($ MILLIONS)
        • FIGURE 9: GLOBAL REVENUE FOR RNAI RESEARCH TOOLS AND REAGENTS BY REGION, 2013-2020 ($ MILLIONS)
      • Market Share
        • TABLE 28: GLOBAL MARKET SHARE OF RNAI RESEARCH TOOLS AND REAGENTS BY REGION, 2014 (%)
        • FIGURE 10: GLOBAL MARKET SHARE OF RNAI RESEARCH TOOLS AND REAGENTS BY REGION, 2014 (%)
      • RNAi Diagnostics
        • TABLE 29: GLOBAL REVENUE FOR RNAI DIAGNOSTICS BY REGION, THROUGH 2020 ($ MILLIONS)
        • FIGURE 11: GLOBAL REVENUE FOR RNAI DIAGNOSTICS BY REGION, 2013-2020 ($ MILLIONS)
      • Market Share
        • TABLE 30: GLOBAL MARKET SHARE OF RNAI DIAGNOSTICS BY REGION, 2014 (%)
        • FIGURE 12: GLOBAL MARKET SHARE OF RNAI DIAGNOSTICS BY REGION, 2014 (%)

CHAPTER 6 - INDUSTRY STRUCTURE

  • RNAI RESEARCH TOOLS AND REAGENTS
    • MARKET LEADERS
      • TABLE 31: LEADING MANUFACTURERS/SUPPLIERS OF RNAI RESEARCH TOOLS AND REAGENTS, 2014
    • MARKET SHARES
      • TABLE 32: GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS FOR RNAI RESEARCH TOOLS AND REAGENTS, 2014 (%)
      • FIGURE 13: GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS FOR RNAI RESEARCH TOOLS AND REAGENTS, 2014 (%)
  • RNAI DIAGNOSTICS
    • MARKET LEADERS
      • TABLE 33: LEADING MANUFACTURERS/SUPPLIERS OF RNAI DIAGNOSTICS, 2014
    • MARKET SHARES
      • TABLE 34: MARKET SHARES OF MANUFACTURERS/SUPPLIERS FOR RNAI DIAGNOSTICS, 2014 (%)
      • FIGURE 14: MARKET SHARES OF MANUFACTURERS/SUPPLIERS FOR RNAI DIAGNOSTICS, 2014 (%)

CHAPTER 7 - PATENT ANALYSIS

  • PATENTS BY YEAR
    • TABLE 35: TOTAL NUMBER OF PATENTS BY YEAR, 2013-AUGUST 2015
    • FIGURE 15: TOTAL NUMBER OF PATENTS BY YEAR, 2013-AUGUST 2015
  • PATENTS BY COUNTRY FOR RNA INTERFERENCE TECHNOLOGIES
    • TABLE 36: NUMBER OF U.S. PATENTS FOR RNAI TECHNOLOGIES BY COUNTRY, 2013-AUGUST 2015
    • TABLE 37: PATENT SHARES FOR RNAI TECHNOLOGIES BY COUNTRY, 2013-AUGUST 2015 (%)
    • FIGURE 16: PATENT SHARES FOR RNAI TECHNOLOGIES BY COUNTRY, 2013-AUGUST 2015 (%)
  • PATENTS BY COMPANY FOR RNA INTERFERENCE TECHNOLOGIES
    • TABLE 38: NUMBER OF U.S. PATENTS FOR RNAI TECHNOLOGIES BY COMPANY, 2013-AUGUST 2015
  • PATENTS BY ASSIGNEE FOR RNA INTERFERENCE TECHNOLOGIES
    • TABLE 39: NUMBER OF PATENTS FOR RNAI TECHNOLOGIES BY TYPE OF ASSIGNEE, 2013-AUGUST 2015
    • FIGURE 17: NUMBER OF PATENTS FOR RNAI TECHNOLOGIES BY TYPE OF ASSIGNEE, 2013-AUGUST, 2015

CHAPTER 8 - CURRENT STATUS

  • INNOVATIVE TECHNOLOGIES AND PLATFORMS FOR RNA INTERFERENCE
  • DYNAMIC POLYCONJUGATE (DPC) PLATFORM-ARROWHEAD RESEARCH CORP.)
  • CONJUGATE DELIVERY PLATFORMS - ESC-GALNAC-CONJUGATE (ALNYLAM PHARMACEUTICALS INC.)
  • LIPID NANOPARTICLE (LNP) TECHNOLOGY (ARBUTUS BIOPHARMA CORP)
  • SIRNA TECHNOLOGY PLATFORM (QUARK PHARMACEUTICALS INC.)
  • MODIFIED MESSENGER RNA THERAPEUTICS PLATFORM (MODERNA THERAPEUTICS)
  • RNAI TECHNOLOGY PLATFORMS (GE DHARMACON)
    • On-TARGETplus siRNAs
    • Reverse Transfection Format (RTF) siRNA Libraries
    • Cherry-Pick RNAi Libraries
    • Human siRNA Libraries
    • Custom siRNA Synthesis
    • Accell siRNA
    • Mouse Accell siRNA Library - Protein Kinases
    • siGENOME siRNAs
    • Lincode siRNAs
    • Lincode siRNA Libraries
    • SMARTvector Lentiviral shRNA
    • SMARTvector Inducible Lentiviral shRNA
    • SMARTvector Lentiviral shRNA Pooled Libraries
    • GIPZ Lentiviral shRNA
    • TRIPZ Inducible Lentiviral shRNA
    • The RNAi Consortium (TRC) Lentiviral shRNA Library
    • Decode Pooled Lentiviral shRNA Screening Libraries and Reagents
    • Viral Packaging Kits
    • siRNA and microRNA Transfection Reagents
    • DharmaFECT Duo Transfection Reagent
  • RNAI TECHNOLOGIES (THERMO FISHER SCIENTIFIC)
    • Silencer Select siRNA
    • Silencer Select siRNA Libraries
    • Stealth RNAi siRNAs
    • BLOCK-iT siRNAs
    • Controls for RNAi Mechanism
  • RNAI TOOLS FROM SIGMA-ALDRICH
    • MISSION siRNA
    • Pre-arrayed siRNA Libraries
    • MISSION In Vivo Quality and iScale Oligos siRNA
    • N-TER Nanoparticle siRNA Transfection System
    • siRNA Controls (Positive and Negative)
    • MISSION shRNA Library
    • MISSION Lentiviral Controls
    • MISSION esiRNA
    • MISSION Human miRNA Mimics
  • LOCKED NUCLEIC ACID (LNA) PLATFORM (ROCHE [SANTARIS PHARMA])
  • TRIFECTA RNAI KIT (INTEGRATED DNA TECHNOLOGIES)
  • PSITEST SYSTEM (INVIVOGEN)
  • SELF-DELIVERABLE RNAI TECHNOLOGY (ADVIRNA)
  • RNAI TECHNOLOGIES (BIONEER CORP)
    • AccuTarget Libraries
    • AccuTarget Control siRNAs from Bioneer
    • AccuTarget Human miRNA Mimic and Inhibitor Library
    • Self-Assembled Micelle Inhibitory RNA (SAMiRNA)
  • POOLED LENTIVIRAL LIBRARIES (CELLECTA INC.)
  • NANOPARTICLE-DRUG CONJUGATES (NDCS) (CERULEAN PHARMA INC.)
  • ALLSTARS RNAI CONTROLS (QIAGEN N.V.)
  • RNAI TECHNOLOGIES (APPLIED BIOLOGICAL MATERIALS)
    • siRNA Adeno-Associated Virus (AAV)
    • iLenti RNAi Expression System
  • LIPID-ENABLED AND UNLOCKED NUCLEIC ACID MODIFIED RNA DELIVERY TECHNOLOGY (ARCTURUS THERAPEUTICS, INC.)
  • ELASTIN-LIKE POLYPEPTIDE (ELP) NANOPARTICLES (PEPTIMED INC.)
  • MICRORNA-BASED DIAGNOSTIC TESTS (ROSETTA GENOMICS)
    • The Rosetta Cancer Origin Test
    • The Rosetta Lung Cancer Test
    • The Rosetta Kidney Cancer Test
    • The Rosetta Mesothelioma Test
  • ATURNAI (SILENCE THERAPEUTICS)
  • DSIRNA-EX-CONJUGATES (DICERNA PHARMACEUTICALS INC.)
  • LODER (SILENSEED LTD.)
  • FACTORS AFFECTING THE RNA INTERFERENCE MARKET
  • CURRENT DRIVERS FOR THE RNA INTERFERENCE TECHNOLOGY MARKET
  • MERGER AND ACQUISITION ACTIVITIES
  • FUNDING FOR DEVELOPMENT OF RNA INTERFERENCE THERAPEUTICS AND TECHNOLOGIES
    • TABLE 40: FUNDING FOR DEVELOPMENT OF RNAI-BASED PRODUCTS AND PLATFORMS, 2013-SEPTEMBER 2015
    • TABLE 41: INVESTMENTS FOR DEVELOPMENT OF RNAI-BASED PRODUCTS AND PLATFORMS, 2013-SEPTEMBER 2015

CHAPTER 9 - COMPANY PROFILES

  • ADVIRNA
  • ALNYLAM PHARMACEUTICALS, INC.
  • APEIRON BIOLOGICS AG
  • APPLIED BIOLOGICAL MATERIALS, INC.
  • ARBUTUS BIOPHARMA CORP. (PREVIOUSLY TEKMIRA PHARMACEUTICALS CORP.)
  • ARCTURUS THERAPEUTICS, INC.
  • ARROWHEAD RESEARCH CORP.
  • ASCLETIS INC.
  • BENITEC BIOPHARMA LTD.
  • BIOGEN IDEC, INC.
  • BIOMICS BIOTECHNOLOGIES CO. LTD.
  • BIONEER CORP.
  • CELLECTA, INC.
  • CERULEAN PHARMA, INC.
  • DICERNA PHARMACEUTICALS, INC.
  • EXIQON A/S
  • F. HOFFMANN-LA ROCHE AG (ROCHE)
  • GENERAL ELECTRIC CO.
  • INTEGRATED DNA TECHNOLOGIES, INC.
  • INVIVOGEN
  • ISIS PHARMACEUTICALS, INC.
  • MARINA BIOTECH, INC.
  • MODERNA THERAPEUTICS
  • MONSANTO CO.
  • NITTO DENKO CORP.
  • PEPTIMED INC.
  • QIAGEN N.V.
  • QUARK PHARMACEUTICALS, INC.
  • REGULUS THERAPEUTICS
  • ROSETTA GENOMICS LTD.
  • RXI PHARMACEUTICALS CORP.
  • SANOFI
  • SIGMA-ALDRICH
  • SILENCE THERAPEUTICS PLC.
  • SILENSEED LTD.
  • SOLSTICE BIOLOGICS
  • SOMAGENICS, INC.
  • SUMITOMO DAINIPPON PHARMA CO. LTD.
  • SYNGENTA INTERNATIONAL AG
  • THE NATIONAL INSTITUTES OF HEALTH (NIH)
  • THE RNAI CONSORTIUM AT BROAD INSTITUTE OF MIT AND HARVARD
  • THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
  • THERMO FISHER SCIENTIFIC, INC.
  • ZELTIA GROUP

CHAPTER 10 - APPENDIX

  • GLOSSARY AND ABBREVIATIONS

LIST OF TABLES

  • SUMMARY TABLE: GLOBAL REVENUE FOR RNA INTERFERENCE TECHNOLOGIES BY TYPE, THROUGH 2020 ($ MILLIONS)
    • TABLE 1: EVOLUTION OF RNA
    • TABLE 2: MICRORNA (MIRNA) DATABASES
    • TABLE 3: SHORT/SMALL INTERFERING RNA (SIRNA) DATABASES
    • TABLE 4: PIWI-INTERACTING RNA (PIRNA) DATABASES
    • TABLE 5: STABILIZATION METHODS FOR LIPID BASED SIRNA DELIVERY SYSTEM
    • TABLE 6: NEW DEVELOPMENTS IN THE RESEARCH PIPELINE OF RNAI THERAPEUTICS AND TECHNOLOGIES AS OF SEPTEMBER 2015
    • TABLE 7: GLOBAL REVENUE FOR RNAI TECHNOLOGIES BY TYPE, THROUGH 2020 ($ MILLIONS)
    • TABLE 8: MARKET SHARE OF RNAI TECHNOLOGIES BY TYPE, 2014 (%)
    • TABLE 9: MODIFICATIONS OF SIRNA
    • TABLE 10: RNAI VECTORS
    • TABLE 11: GLOBAL REVENUE FOR RNAI RESEARCH TOOLS AND REAGENTS, THROUGH 2020 ($ MILLIONS)
    • TABLE 12: MARKET SHARE OF RNAI RESEARCH TOOLS AND REAGENTS, 2014 (%)
    • TABLE 13: DISEASE-SPECIFIC TARGET GENES/PROTEINS FOR RNAI THERAPEUTICS
    • TABLE 14: GLOBAL PHARMACEUTICAL MARKET, THROUGH 2020 ($ BILLIONS)
    • TABLE 15: GLOBAL PHARMACEUTICAL MARKET SHARES BY REGION, 2014 (%)
    • TABLE 16: TOP GLOBAL PHARMACEUTICAL COMPANIES BY SALES, 2014 ($ MILLIONS)
    • TABLE 17: GLOBAL OUTLOOK OF THERAPEUTIC SPENDING BY DISEASE, THROUGH 2018 ($ BILLION/%)
    • TABLE 18: NUMBER OF PUBLICATIONS ASSOCIATED WITH MIRNA AND DISEASES, OCTOBER 2015
    • TABLE 19: MIRNA IN VARIOUS CANCER TYPES
    • TABLE 20: MIRNA AND TARGET GENE PAIRS IN VARIOUS CANCER TYPES
    • TABLE 21: BIOMARKERS IN VARIOUS CANCER TYPES
    • TABLE 22: GLOBAL REVENUE MARKET FOR RNAI DIAGNOSTICS, THROUGH 2020 ($ MILLIONS)
    • TABLE 23: GLOBAL REVENUE FOR MIRNA RESEARCH TOOLS, THROUGH 2020 ($ MILLIONS)
    • TABLE 24: SAFETY ISSUES WITH RNAI CROP IMPROVEMENT
    • TABLE 25: PLANT IMPROVEMENT AREAS THROUGH RNAI TECHNOLOGIES
    • TABLE 26: REGIONS, GENES AND APPLICATION OF RNAI-TARGETING ORGANISMS FOR IMPROVEMENT OF CROPS
    • TABLE 27: GLOBAL REVENUE FOR RNAI RESEARCH TOOLS AND REAGENTS BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 28: GLOBAL MARKET SHARE OF RNAI RESEARCH TOOLS AND REAGENTS BY REGION, 2014 (%)
    • TABLE 29: GLOBAL REVENUE FOR RNAI DIAGNOSTICS BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 30: GLOBAL MARKET SHARE OF RNAI DIAGNOSTICS BY REGION, 2014 (%)
    • TABLE 31: LEADING MANUFACTURERS/SUPPLIERS OF RNAI RESEARCH TOOLS AND REAGENTS, 2014
    • TABLE 32: GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS FOR RNAI RESEARCH TOOLS AND REAGENTS, 2014 (%)
    • TABLE 33: LEADING MANUFACTURERS/SUPPLIERS OF RNAI DIAGNOSTICS, 2014
    • TABLE 34: MARKET SHARES OF MANUFACTURERS/SUPPLIERS FOR RNAI DIAGNOSTICS, 2014 (%)
    • TABLE 35: TOTAL NUMBER OF PATENTS BY YEAR, 2013-AUGUST 2015
    • TABLE 36: NUMBER OF U.S. PATENTS FOR RNAI TECHNOLOGIES BY COUNTRY, 2013-AUGUST 2015
    • TABLE 37: PATENT SHARES FOR RNAI TECHNOLOGIES BY COUNTRY, 2013-AUGUST 2015 (%)
    • TABLE 38: NUMBER OF U.S. PATENTS FOR RNAI TECHNOLOGIES BY COMPANY, 2013-AUGUST 2015
    • TABLE 39: NUMBER OF PATENTS FOR RNAI TECHNOLOGIES BY TYPE OF ASSIGNEE, 2013-AUGUST 2015
    • TABLE 40: FUNDING FOR DEVELOPMENT OF RNAI-BASED PRODUCTS AND PLATFORMS, 2013-SEPTEMBER 2015
    • TABLE 41: INVESTMENTS FOR DEVELOPMENT OF RNAI-BASED PRODUCTS AND PLATFORMS, 2013-SEPTEMBER 2015

LIST OF FIGURES

  • SUMMARY FIGURE: GLOBAL REVENUE FOR RNA INTERFERENCE TECHNOLOGIES BY TYPE, 2013-2020 ($ MILLIONS)
    • FIGURE 1: GLOBAL REVENUE FOR RNAI TECHNOLOGIES BY TYPE, 2013-2020 ($ MILLIONS)
    • FIGURE 2: MARKET SHARE OF RNAI TECHNOLOGIES BY TYPE, 2014 (%)
    • FIGURE 3: GLOBAL REVENUE FOR RNAI RESEARCH TOOLS AND REAGENTS, 2013-2020 ($ MILLIONS)
    • FIGURE 4: MARKET SHARE OF RNAI RESEARCH TOOLS AND REAGENTS, 2014 (%)
    • FIGURE 5: GLOBAL PHARMACEUTICAL SALES MARKET,2013-2020 ($ BILLIONS)
    • FIGURE 6: GLOBAL PHARMACEUTICAL MARKET SHARES BY REGION, 2014 (%)
    • FIGURE 7: GLOBAL REVENUE MARKET FOR RNAI DIAGNOSTICS, 2013-2020 ($ MILLIONS)
    • FIGURE 8: GLOBAL REVENUE FOR MIRNA RESEARCH TOOLS,2013-2020 ($ MILLIONS)
    • FIGURE 9: GLOBAL REVENUE FOR RNAI RESEARCH TOOLS AND REAGENTS BY REGION, 2013-2020 ($ MILLIONS)
    • FIGURE 10: GLOBAL MARKET SHARE OF RNAI RESEARCH TOOLS AND REAGENTS BY REGION, 2014 (%)
    • FIGURE 11: GLOBAL REVENUE FOR RNAI DIAGNOSTICS BY REGION, 2013-2020 ($ MILLIONS)
    • FIGURE 12: GLOBAL MARKET SHARE OF RNAI DIAGNOSTICS BY REGION, 2014 (%)
    • FIGURE 13: GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS FOR RNAI RESEARCH TOOLS AND REAGENTS, 2014 (%)
    • FIGURE 14: MARKET SHARES OF MANUFACTURERS/SUPPLIERS FOR RNAI DIAGNOSTICS, 2014 (%)
    • FIGURE 15: TOTAL NUMBER OF PATENTS BY YEAR, 2013-AUGUST 2015
    • FIGURE 16: PATENT SHARES FOR RNAI TECHNOLOGIES BY COUNTRY, 2013-AUGUST 2015 (%)
    • FIGURE 17: NUMBER OF PATENTS FOR RNAI TECHNOLOGIES BY TYPE OF ASSIGNEE, 2013-AUGUST, 2015
Back to Top
전화 문의
F A Q